These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 34853735)

  • 1. Current Trends in the Duration of Anticoagulant Therapy for Venous Thromboembolism: A Systematic Review.
    Alexander P; Visagan S; Issa R; Gorantla VR; Thomas SE
    Cureus; 2021 Oct; 13(10):e18992. PubMed ID: 34853735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis.
    Franco L; Giustozzi M; Agnelli G; Becattini C
    J Thromb Haemost; 2017 Jun; 15(6):1142-1154. PubMed ID: 28316124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of DVT: how long is enough and how do you predict recurrence.
    Agnelli G; Becattini C
    J Thromb Thrombolysis; 2008 Feb; 25(1):37-44. PubMed ID: 17906973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
    Robertson L; Yeoh SE; Ramli A
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.
    Schulman S; Granqvist S; Holmström M; Carlsson A; Lindmarker P; Nicol P; Eklund SG; Nordlander S; Lärfars G; Leijd B; Linder O; Loogna E
    N Engl J Med; 1997 Feb; 336(6):393-8. PubMed ID: 9010144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.
    Huisman MV; Bounameaux H
    Semin Vasc Med; 2005 Aug; 5(3):276-84. PubMed ID: 16123915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism.
    Akwaa F; Spyropoulos AC
    Curr Med Res Opin; 2014 Nov; 30(11):2179-90. PubMed ID: 25105309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era.
    Toth PP
    Vasc Health Risk Manag; 2016; 12():23-34. PubMed ID: 26929637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
    Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
    PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic drugs: part I.
    Gallus AS; Hirsh J
    Drugs; 1976; 12(1):41-68. PubMed ID: 789043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study).
    Tullett J; Murray E; Nichols L; Holder R; Lester W; Rose P; Hobbs FD; Fitzmaurice D
    BMC Cardiovasc Disord; 2013 Mar; 13():16. PubMed ID: 23497371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing pulmonary embolism from presentation to extended treatment.
    Cohen AT; Dobromirski M; Gurwith MM
    Thromb Res; 2014 Feb; 133(2):139-48. PubMed ID: 24182642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation.
    Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Barba M; Yosuico VED; Terrenato I; Sperati F; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD006466. PubMed ID: 29285754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The optimal duration of anticoagulant treatment following pulmonary embolism].
    Couturaud F
    Rev Mal Respir; 2011 Dec; 28(10):1265-77. PubMed ID: 22152935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venous thromboembolism in cancer patients.
    Deng A; Galanis T; Graham MG
    Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on extended treatment for venous thromboembolism.
    Peñaloza-Martínez E; Demelo-Rodríguez P; Proietti M; Soria Fernández-Llamazares G; Llamazares-Mendo C; Álvarez-Sala Walther L; Marra AM; Del Toro-Cervera J
    Ann Med; 2018 Dec; 50(8):666-674. PubMed ID: 30345825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
    Kearon C; Gent M; Hirsh J; Weitz J; Kovacs MJ; Anderson DR; Turpie AG; Green D; Ginsberg JS; Wells P; MacKinnon B; Julian JA
    N Engl J Med; 1999 Mar; 340(12):901-7. PubMed ID: 10089183
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.